The Human Microbiome Project (HMP) was launched in 2007 by the US National Institutes of Health, with the goal of cataloguing the complex communities of microbial organisms found within and upon our bodies, and to characterise how these microbial communities might differ in the context of various states of disease and health in humans. Full characterisation of the microbiome---not to mention its related gene products and metabolites---is no small endeavour, given the astonishing fact that each individual human being hosts roughly 100 trillion microbes. When one considers the potential genetic and phenotypic impact of such an enormous number of living organisms cohabiting our bodies, it might come as no surprise that dysfunction or so-called dysbiosis of the microbiome has been associated with a long list of human diseases and various states of health. In some contexts, it even appears that a dysbiotic microbiome---and perhaps even specific taxa---might have a direct causal connection to disease onset, development, or both. For many diseases, although differences in composition or diversity might strongly associate with an unhealthy state, whether the microbiome plays a regulatory role, or whether the dysbiosis is instead a consequence of the disease state, has yet to be discerned.

However, there is no question that our health status is deeply dependent upon the state of our microbiome. It is therefore crucial that we begin to untangle this complex relationship and to tease apart mechanisms of how our microbiome might contribute to health and disease. We are thus very pleased to launch a series of commissioned reviews focusing on these issues. We hope this series will serve as a centralised platform for scientists and clinicians who want to learn more about therapeutic implications gleaned from recent microbiome research, and to consider how these insights may begin to affect clinical practice. In the coming months, all reviews related to the series and select research papers will be collated in a virtual online issue entitled Microbiome in the Clinic.

In this issue of *EBioMedicine* we publish the first five reviews in the series. Faecal microbiota transplantation (FMT) is a well-studied method for treating *Clostridioides difficile* (*C. diff*) infections, and two reviews in this issue from Wortelboer and colleagues and Wardill and colleagues look beyond *C. diff* treatment to consider how FMT could be applied in other disease contexts such as cancer and metabolic syndrome. It is becoming increasingly clear that our microbiome affects the way we respond to drugs, and a review by Guthrie and Kelly takes a closer look at both the ways in which drug responses might be altered and how researchers could in turn aim to predict and improve these responses. Thaiss and colleagues summarise our current understanding of how microbial-derived metabolites might work and discuss the translational potential of manipulating these metabolites to improve health outcomes. Finally, Dahlin and Prast-Nielsen examine the potential role the microbiome could play in epilepsy and in outcomes of treatment of patients with epilepsy with a ketogenic diet. This issue also features six primary research manuscripts focusing on the microbiome, including a longitudinal analysis in Parkinson's disease patients and a preclinical study looking at the connection between the gut--brain axis and cardiorespiratory control.

Given the complexity of microbiome research, the HMP has followed a comprehensive strategy of collecting multi-omic datasets from both microbiomes and their respective human hosts. These large datasets will lay the groundwork for future studies aimed at piecing together causal and mechanistic pathways and are a necessary first step. Three papers arising from a second, disease-focused phase of the HMP were published in the May 29^th^ issues of *Nature* and *Nature Medicine*. These studies examine longitudinal cohorts in three separate contexts---pregnancy and preterm birth, inflammatory bowel disease, and prediabetes and are unique in the scale and breadth of their data analyses. Whereas none of these studies appear to expose any smoking-gun microbes that are directly responsible for disease, they do begin to reveal meaningful patterns within and between individuals that in the short term could be the basis for powerful diagnostics and risk-assessment tools. It will take a multidisciplinary approach to solve the long-term challenges of discerning causative pathways, and to understand whether we can manipulate these pathways to therapeutic benefit.

June 27^th^, 2019, marks the second annual World Microbiome Day, aimed at bringing awareness to these fascinating microbes. As the microbiome research field evolves, we remain steadfast at the interface between disease mechanisms and clinical translation. Along with this new series, Microbiome in the Clinic, we aim to publish strong microbiome studies in the translational space, and to serve as a forum for further discussion on how we can help move the microbiome research field forward toward improving human health.
